March 8, 2018 / 2:40 PM / 5 months ago

美国热股:Vascular研发的抗癌药在后期临床试验中失败,股价暴跌逾60%

路透3月8日 - 以色列生物制药公司Vascular Biogenics研发的癌症药物VB-111在后期临床试验中失败。

Vascular股价暴跌63%,报2.6美元。(完) (编译 白云; 审校)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below